Preclinical Development – Chemical
2019 PharmSci 360
For developing a successful orally Inhaled drug product, the drug/formulation/device combination has to fulfill a number of criteria. The product should deliver the drug with high efficiency into the lung if possible to the site relevant to the action. It should be retained in the lung, be cleared efficiently from the body after absorption into the blood stream and show low oral bioavailability. This presentation will review preclinical models for pulmonary delivery. In vitro and in silico methods for assessing the fate of the drug in the lung will be discussed. This will include lung deposition and dissolution as well as suitable cell culture, isolated perfused lung and animal models. The presentation will include case studies, that demonstrate the importance of applying pre-clinical models during early stage drug development.